Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20163447 | 0.91 | LSS (0.36) | SSTR4 | |
| SCHEMBL19485524 | 0.89 | LSS (0.31) | SSTR4 | |
| SCHEMBL20173486 | 0.89 | SSTR4 (0.31) | SSTR4 | |
| SCHEMBL18295981 | 0.88 | SSTR4 (0.31) | SSTR4 | |
| SCHEMBL22149873 | 0.87 | FDPS (0.31) | SSTR4 | |
| SCHEMBL20191131 | 0.85 | EPHX2 (0.30) | — | |
| SCHEMBL20163519 | 0.85 | LSS (0.32) | CHEK2 | |
| SCHEMBL20163522 | 0.85 | LSS (0.32) | CHEK2 | |
| SCHEMBL20173481 | 0.85 | GPR183 (0.33) | — | |
| SCHEMBL20163534 | 0.85 | MEN1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255415-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BREAST CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-08-13 | — | — | US | disclosed |
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | BRCA1, ESR2, ESR1 | CHEK2 863/4885SSTR4 2377/4885 |
| US-20200255415-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BREAST CANCER | BRCA1, ESR2, ESR1 | CHEK2 657/4885SSTR4 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.